Last reviewed 2026-04-20 · How we verify

Dimepropion (METAMFEPRAMONE)

Phase 2 active Small molecule

Dimepropion (generic name: METAMFEPRAMONE) is a drug. It is currently in Phase 2 development.

Dimepropion is a central nervous system stimulant that works by increasing the activity of certain neurotransmitters in the brain.

Dimepropion, also known as Metamfepramone, is a small molecule drug with unknown target and drug class. It is currently owned by an unknown entity, and its commercial status is unclear. The drug is used to treat unknown indications, and its safety profile and pharmacokinetic properties are not well-documented. Further research is needed to fully understand the properties and uses of Dimepropion. As a result, it is not possible to provide a comprehensive summary of this drug at this time.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	METAMFEPRAMONE
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Imagine your brain is a city with many different streets and intersections. Dimepropion helps to increase the flow of traffic on certain streets, allowing messages to be sent more quickly and efficiently. This can help to improve focus, attention, and energy levels, but it can also have negative effects if taken in excess.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Dimepropion CI brief — competitive landscape report
Dimepropion updates RSS · CI watch RSS

Frequently asked questions about Dimepropion

What is Dimepropion?

Dimepropion (METAMFEPRAMONE) is a Small molecule drug.

How does Dimepropion work?

Dimepropion is a central nervous system stimulant that works by increasing the activity of certain neurotransmitters in the brain.

What is the generic name of Dimepropion?

METAMFEPRAMONE is the generic (nonproprietary) name of Dimepropion.

What development phase is Dimepropion in?

Dimepropion is in Phase 2.

Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing